SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (2978)6/1/2020 6:36:22 PM
From: Miljenko Zuanic1 Recommendation

Recommended By
CuttingEdge Bio

  Respond to of 3557
 
Tidbit, mITT NSCLC OS (FDA approved PDL1 test, N= 563, from N=712), slide 18:
HR= 0.566 p=0.002 from
HR= 0.676 p=0.002

None like post-hock analysis, but this was directed/requested by FDA!



To: Miljenko Zuanic who wrote (2978)6/3/2020 12:55:22 PM
From: CuttingEdge Bio  Read Replies (1) | Respond to of 3557
 
If ego was the takeaway, that's really missing the point. I am seeing clearly this is a snowball rolling down the mountain, REGN will become a big player in oncology in the near future.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News